Cellular 'energetic switch' could help separate drug rewards from natural pleasure
Alcohol, opioids, nicotine, cocaine and other addictive substances are known to influence the brain's reward system, the network of brain regions involved in the reinforcement of pleasure-seeking behaviors. Many of these drugs trigger large surges in dopamine, a chemical messenger released in the brain that supports communication between cells, motivation-driven behaviors and learning.
Researchers at China's State Key Laboratory of Biomedical Analysis have identified a cellular mechanism in mice that may help distinguish the brain's response to natural rewards from its response to addictive drugs such as opioids and methamphetamine. The study, published in Nature Neuroscience, focuses on mitochondria and their role in energy metabolism within the brain's reward system.
Opioids, like heroin and fentanyl, and methamphetamine, a potent stimulant, trigger large surges in dopamine, a neurotransmitter involved in motivation-driven behaviors, learning, and pleasure-seeking. Repeated drug use can cause compulsive behavior and weaken responses to natural rewards like food and social interactions.
The research team, led by Xin Pan, used fluorescent probes, in vivo fiber photometry, optogenetics, gene knockout, and pharmacological blockade to study the effects of addictive drugs on mitochondria within dopamine-producing nerve endings in the mouse nucleus accumbens. This brain region is crucial for reward learning and processing pleasurable stimuli.
The study found that opioids and methamphetamine caused calcium ions to enter mitochondria through the mitochondrial calcium uniporter (MCU) channel, leading to selective drug-induced dopamine release and addiction-like behaviors. However, this mechanism did not affect the mice's responses to natural rewards. Deleting the MCU gene reduced drug-induced dopamine release and prevented addiction-like behaviors without impacting natural reward responses.
The findings suggest that targeting the MCU channel could lead to addiction treatments with fewer side effects, as this pathway is specific to the pathological processes underlying addiction. However, further research in humans is needed to confirm these results and explore potential treatment applications.
Written by urgent.news from Medical Xpress's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
